Topical Safety Study of Topical Diltiazem Hydrochloride

NCT ID: NCT01816529

Last Updated: 2013-08-21

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE1
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-03-31
• Study Completion Date: 2013-09-30

Brief Summary

The goal of this study will be to determine the potential of Diltiazem Hydrochloride 2% Cream to induce sensitization by repeated topical application to the skin of healthy subjects under controlled conditions.

Detailed Description

The primary objective of this study will be to determine the potential of Diltiazem Hydrochloride 2% Cream and its vehicle to induce sensitization by repeated topical application to the skin of healthy subjects under controlled conditions. In addition, the irritation potential of the investigational products will be assessed during the Induction Phase and safety will be assessed by evaluation of any adverse events (AEs) reported during the study.

Conditions

Diltiazem Skin Sensitivity.

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Topical Diltiazem Hydrochloride 2% Cream

0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.

Group Type: EXPERIMENTAL

Diltiazem Hydrochloride 2% Cream

Intervention Type: DRUG

0.2 g applied topically to the infrascapular area of the back.

Vehicle Cream

0.2 g cream applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.

Group Type: PLACEBO_COMPARATOR

Vehicle Cream

Intervention Type: DRUG

Vehicle Cream, 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.

0.1% solution of sodium lauryl sulfate (SLS)

0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.

Group Type: ACTIVE_COMPARATOR

0.1% solution of sodium lauryl sulfate (SLS)

Intervention Type: DRUG

0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.

0.9% Saline

0.2 mL applied topically to the infrascapular area of the back under occlusive patch conditions, 3 times weekly for 3 weeks and one time at Challenge. A total of 10 patch applications over 6-8 weeks.

Group Type: PLACEBO_COMPARATOR

Saline (0.9%)

Intervention Type: DRUG

0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.

Interventions

Diltiazem Hydrochloride 2% Cream

0.2 g applied topically to the infrascapular area of the back.

Intervention Type: DRUG

Vehicle Cream

Vehicle Cream, 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.

Intervention Type: DRUG

0.1% solution of sodium lauryl sulfate (SLS)

0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.

Intervention Type: DRUG

Saline (0.9%)

0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Are healthy males or females (to be confirmed by medical history);
• Are 18 years of age or older;
• In the case of females of childbearing potential, are using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide, abstinence, partner's vasectomy). Abstinence or vasectomies are acceptable if the female subject agrees to implement one of the other acceptable methods of birth control if her lifestyle/partner changes;
• In the case of females of childbearing potential: have a negative urine pregnancy test (UPT) at Screening, and are willing to submit to a pregnancy test at the end of study (EOS);
• Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events;
• Are of any skin type or race, providing the skin pigmentation will allow discernment of erythema;
• Read, understand, and provide signed informed consent.

Exclusion Criteria

• Have sick sinus syndrome except in the presence of a functioning ventricular pacemaker (confirmed via medical history);
• Have second-or third-degree AV block except in the presence of a functioning ventricular pacemaker (confirmed via medical history);
• Have hypotension (less than 90 mm Hg systolic, determined by performing vital signs);
• Have acute myocardial infarction and pulmonary congestion documented by x-ray (confirmed via medical history);
• Have any visible skin disease at the application site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test site reaction;
• Are not willing to refrain from using topical/systemic analgesics such as aspirin (daily use of 81 mg aspirin is acceptable), Aleve, Motrin, Advil, or Nuprin for 72 hours prior to and during the study (occasional use of acetaminophen will be permitted);
• Are using systemic/topical corticosteroids for 3 weeks prior to and during the study, or systemic/topical antihistamines for 72 hours prior to and during the study;
• Are using medication which, in the opinion of the investigative personnel, will interfere with the study results, including anti-inflammatory medications;
• Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions, or similar products on the back during the study;
• Have psoriasis and/or active atopic dermatitis/eczema;
• Are females who are pregnant, plan to become pregnant during the study, or are breast-feeding a child;
• Have a known sensitivity to constituents present in the material being evaluated;
• Have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site;
• Have received treatment for any type of internal cancer within 5 years prior to study entry;
• Have a history of, or are currently being treated for skin cancer;
• Are currently participating in any clinical testing,
• Have any known sensitivity to adhesives; and/or
• Have received any investigational treatment(s) within 4 weeks prior to study entry.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Ventrus Biosciences, Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

TKL Research

Paramus, New Jersey, United States

Countries

United States

Other Identifiers

VEN307-DERM-001

Identifier Type: -

Identifier Source: org_study_id